Significance of human microbiome in breast cancer: Tale of an invisible and an invincible

Chadha, Jatin; Nandi, Deeptashree; Atri, Yama; Nag, Alo

doi:10.1016/j.semcancer.2020.07.010

Cited by 42 publications

(37 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The imbalance of the gut microbiota leads to an increased risk of endotoxemia, insulin resistance, systemic inflammation, obesity and metabolic disorders, non-alcoholic fatty liver diseases, and cancer [23][24][25][26] . Currently, probiotics and prebiotics can restore the normal flora of the gut microbiome and show favorable efficacy in the treatment of some pathological conditions including liver diseases 9,27,28 .…”

Section: Discussionmentioning

confidence: 99%

Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study

et al. 2021

View full text Add to dashboard Cite

The gut microbiota system plays vital role in liver diseases. This study aimed to address the diversity of gut microbiota and its correlations with clinical parameters in healthy individuals, chronic liver disease (CLD), and hepatocellular carcinoma (HCC) patients. Fecal specimens of 9 healthy individuals, 11 CLD, and 21 HCC were collected. The diversity of gut microbiota was examined by PCR and Illumina MiSeq sequencing and analyzed using 16S rRNA gene sequencing database. The correlations between gut microbiota and the clinical parameters of participants were also addressed. Compared to healthy individuals, Firmicutes on a phylum level decreased in CLD and HCC patients and Proteobacteria increased (p < 0.05). The composition of Blautia on a genus level in CLD and HCC patients significantly decreased compared to healthy controls (p < 0.05). Firmicutes composition was negatively associated with age and number of males (p < 0.05), and was positively associated with monocytes, high density lipoprotein cholesterol (HDL-C), and estimated glomerular filtration rate (eGFR) levels (p < 0.05). On a genus level, Blautia composition was negatively associated with cirrhosis, age, and number of males (p < 0.01); while it was positively associated with red blood cells (RBC), triglycerides, HDL-C, and lymphocytes levels (p < 0.05). Conclusively, there was a significant compositional difference in 3 gut microbiota in CLD and HCC patients compared with healthy subjects.Firmicutes and Blautia in gut microbiota system lessened in CLD and HCC patients. Clinical biochemical parameters have an impact on the diversity of gut microbiota in liver diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Variations in the microbiome of cancer patients with different cancer stages have already been known in the literature. For instance, the species of Firmicutes and Bacteroides are dominant in the invasive and benign BC, whereas some of the species such as Fusobacterium, Atopobium, and Lactobacillus are enriched in malignant breast tissues (e.g., Hieken et al, 2016;Chadha et al, 2020). The recent studies about the role of the microbiome in different cancers and neurodegenerative diseases reveal that there are some common species observed in all cancer tissues.…”

Section: Discussionmentioning

confidence: 99%

Tissue Microbiome Associated With Human Diseases by Whole Transcriptome Sequencing and 16S Metagenomics

Salihoğlu

Önal-Süzek

2021

Front. Genet.

View full text Add to dashboard Cite

In recent years, a substantial number of tissue microbiome studies have been published, mainly due to the recent improvements in the minimization of microbial contamination during whole transcriptome analysis. Another reason for this trend is due to the capability of next-generation sequencing (NGS) to detect microbiome composition even in low biomass samples. Several recent studies demonstrate a significant role for the tissue microbiome in the development and progression of cancer and other diseases. For example, the increase of the abundance of Proteobacteria in tumor tissues of the breast has been revealed by gene expression analysis. The link between human papillomavirus infection and cervical cancer has been known for some time, but the relationship between the microbiome and breast cancer (BC) is more novel. There are also recent attempts to investigate the possible link between the brain microbiome and the cognitive dysfunction caused by neurological diseases. Such studies pointing to the role of the brain microbiome in Huntington’s disease (HD) and Alzheimer’s disease (AD) suggest that microbial colonization is a risk factor. In this review, we aim to summarize the studies that associate the tissue microbiome, rather than gut microbiome, with cancer and other diseases using whole-transcriptome analysis, along with 16S rRNA analysis. After providing several case studies for each relationship, we will discuss the potential role of transcriptome analysis on the broader portrayal of the pathophysiology of the breast, brain, and vaginal microbiome.

show abstract

“…This Gram-positive agent was found to be elevated in BC tissue. This has already been shown to promote proliferation of tumour cells in vitro by metabolising progesterone to 5αP (Urbaniak et al, 2016;Chadha et al, 2020).…”

Section: Dynamic Evolution Of Gut and Breast Microbiota Through Breasmentioning

confidence: 95%

“…There is evidence that E. coli, Staphylococcus epidermidis, and E. faecalis have the ability to inflict DNA damage through production of genotoxins (including colibactin), hydroxyl and superoxide radicals (Urbaniak et al, 2016;Eslami-S et al, 2020). In addition, E. coli colibactin can induce senescence-associated secretory phenotype of growth factors capable of stimulating cell proliferation and tumour progression (Fulbright et al, 2017;Chadha et al, 2020).…”

Section: Dynamic Evolution Of Gut and Breast Microbiota Through Breasmentioning

confidence: 99%

Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine

et al. 2021

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy and the second cause of cancer-specific death in women from high-income countries. Recently, gut microbiota dysbiosis emerged as a key player that may directly and/or indirectly influence development, treatment, and prognosis of BC through diverse biological processes: host cell proliferation and death, immune system function, chronic inflammation, oncogenic signalling, hormonal and detoxification pathways. Gut colonisation occurs during the prenatal period and is later diversified over distinct phases throughout life. In newly diagnosed postmenopausal BC patients, an altered faecal microbiota composition has been observed compared with healthy controls. Particularly, β-glucuronidase bacteria seem to modulate the enterohepatic circulation of oestrogens and their resorption, increasing the risk of hormone-dependent BC. Moreover, active phytoestrogens, short-chain fatty acids, lithocholic acid, and cadaverine have been identified as bacterial metabolites influencing the risk and prognosis of BC. As in gut, links are also being made with local microbiota of tumoural and healthy breast tissues. In breast microbiota, different microbial signatures have been reported, with distinct patterns per stage and biological subtype. Total bacterial DNA load was lower in tumour tissue and advanced-stage BC when compared with healthy tissue and early stage BC, respectively. Hypothetically, these findings reflect local dysbiosis, potentially creating an environment that favours breast tumour carcinogenesis (oncogenic trigger), or the natural selection of microorganisms adapted to a specific microenvironment. In this review, we discuss the origin, composition, and dynamic evolution of human microbiota, the links between gut/breast microbiota and BC, and explore the potential implications of metabolomics and pharmacomicrobiomics that might impact BC development and treatment choices toward a more personalised medicine. Finally, we put in perspective the potential limitations and biases regarding the current microbiota research and provide new horizons for stronger accurate translational and clinical studies that are needed to better elucidate the complex network of interactions between host, microorganisms, and drugs in the field of BC.

show abstract

Significance of human microbiome in breast cancer: Tale of an invisible and an invincible

Cited by 42 publications

References 160 publications

Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study

Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study

Tissue Microbiome Associated With Human Diseases by Whole Transcriptome Sequencing and 16S Metagenomics

Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine

Contact Info

Product

Resources

About